Quick Read
- Novo Nordisk raised its 2026 guidance following better-than-expected Q1 performance driven by high Wegovy pill demand.
- The Wegovy oral tablet reached over 200,000 weekly prescriptions in the U.S. by mid-April, marking a record launch for the company.
- The company faces intensifying competition from Eli Lilly’s Foundayo, though early prescription data favors the Wegovy pill’s market penetration.
BAGSVÆRD, Denmark (Azat TV) – Novo Nordisk has raised its full-year 2026 financial guidance after reporting a stronger-than-anticipated performance in its obesity care segment, driven primarily by the rapid U.S. adoption of its new oral Wegovy tablet. The pharmaceutical giant revealed that the Wegovy pill, which launched in the U.S. on January 5, 2026, exceeded 200,000 weekly prescriptions by mid-April, marking what the company described as its strongest-ever GLP-1 volume launch.
Wegovy Pill Adoption Reshapes Market Dynamics
The successful rollout of the Wegovy oral formulation has provided a significant tactical advantage for Novo Nordisk as it navigates a hyper-competitive GLP-1 landscape. According to the company’s Q1 2026 earnings report, sales for the Wegovy pill reached 2,256 million DKK, significantly outpacing analyst estimates. With more than 2 million total prescriptions since its January launch, the product is currently defining a new category for oral peptide-based obesity treatments.
This performance is particularly notable given the intense rivalry with Eli Lilly, which recently launched its own weight-loss pill, Foundayo. While Lilly has seen rapid growth in its injectable portfolio, industry analysts noted that early prescription data for Foundayo has lagged behind the momentum established by Novo Nordisk’s oral offering. The ability of the Wegovy pill to capture market share in the direct-to-consumer channel remains a critical factor in Novo Nordisk’s revised outlook.
Financial Performance and Strategic Adjustments
Novo Nordisk reported total Q1 2026 sales of 96.8 billion DKK, a 32% increase on a constant currency basis, though this figure was buoyed by a significant non-recurring 340B Drug Pricing Program provision reversal. When excluding this one-time impact, adjusted sales decreased by 4% due to lower realized prices in the U.S. market. Despite the adjusted contraction, the company’s decision to hike its 2026 guidance reflects management’s confidence in the continued volume growth of its GLP-1 portfolio.
Pipeline Progress and Future Outlook
Beyond the Wegovy pill, the company continues to expand its clinical footprint. In March, the FDA approved Wegovy HD—an injectable semaglutide 7.2 mg formulation—which demonstrated 20.7% mean weight loss in clinical trials. Furthermore, the company has initiated the phase 3 program for its experimental drug, zenagamtide, and successfully met endpoints for its sickle cell disease treatment, etavopivat. As the company prepares for the international launch of the Wegovy pill in the second half of 2026, the focus remains on scaling production to meet high global demand.
The aggressive push into oral GLP-1 therapies represents a strategic pivot for Novo Nordisk as it attempts to defend its market dominance against Eli Lilly; the company’s ability to maintain this momentum will depend on whether the Wegovy pill can sustain its early prescription lead without significantly cannibalizing the company’s established injectable product lines.